The [TargaCell] non-invasive delivery procedure would make it much easier to enroll patients {in clinical trials}. Regarding current methods, “… where [do] these cells go once they are injected into the wall because clearly most of them don’t remain there for very long.
Gary Schaer, MD
Professor Cardiology & Director of Translational Medicine Research, Rush University, Chicago, IL
The [TargaCell] non-invasive delivery procedure would make it much easier to enroll patients {in clinical trials}
Regarding current methods, “… where [do] these cells go once they are injected into the wall because clearly most of them don’t remain there for very long.
Douglas Losordo, MD
Executive Vice-President for Global Research & Development & Chief Medical Officer, Caladrius; (while Prof. Cardiology Northwestern University Feinberg School of Medicine)
